pharmaphorum
SEPTEMBER 2, 2020
The UK’s medicines regulator has published long-awaited guidance on regulation of medicines and medical devices as the UK approaches the end of its Brexit transition period at the end of the year. This would see the UK mirroring decisions made by the European Medicines Agency, while also laying out a process should companies wish to file for a separate approval in the UK.
Outsourcing Pharma
SEPTEMBER 3, 2020
Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
SEPTEMBER 4, 2020
The first digital session of Medical Device Innovation Summit concludes on a positive note with industry leaders addressing burning topics to promote innovation in the medical equipment industry. From challenges like lack of regulatory systems to its new found potential of manufacturing indigenous products on a large scale, the summit successfully addressed discussions on new.
Pharma Times
SEPTEMBER 1, 2020
Rybelsus is the world’s first and only oral GLP-1 receptor agonist
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
SEPTEMBER 2, 2020
Digital health firm Mobio Interactive has closed a $1.8 million seed fund to advance development of its meditation app Am Mindfulness. Mobio said that the app, known as Am for short, is the first and only meditation app to outperform placebo in randomised controlled trials. MI’s Seed raise was led by the Singapore-based Verge HealthTech Fund along with Atlas Asset Management , Creative Ventures and VC giant SOSV.
Outsourcing Pharma
AUGUST 31, 2020
A recent study from healthcare insights company Sermo shares information and perspectives that trial and pharma professionals could learn from.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Times
SEPTEMBER 3, 2020
Scientists have discovered that hard-to-treat pancreatic cancer hijacks a key immune system response
pharmaphorum
SEPTEMBER 3, 2020
UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its depression treatment based on psilocybin – an active ingredient that can be found in magic mushrooms. In a filing with the US financial regulator Compass laid out its plans to develop the drug known as COMP360, which is a crystalline formulation of psilocybin in phase 2b clinical development in patients who have not responded to standard therapy for depression.
Outsourcing Pharma
SEPTEMBER 1, 2020
A new scientific report offers a comprehensive review of protein targets, associated COVID-19 drug candidates to date and other revealing information.
Pharma Mirror
SEPTEMBER 2, 2020
Jacobson Pharma Corporation Limited (“Jacobson Pharma” or the Group”; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong, announced the signing of a letter of intent (“Letter of Intent”) with Fosun Industrial Co.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
SEPTEMBER 3, 2020
NICE has concerns with the evidence submitted but Janssen insists the nasal spray is a cost-effective use of NHS resources
pharmaphorum
SEPTEMBER 3, 2020
NICE has rejected regular NHS funding for Janssen’s depression spray Spravato (esketamine) for a second time, although the company says it could salvage the situation by providing further data and “additional discussions”. This will likely see the company drop its price further after already offering a commercially confidential discount to the NHS following European approval late last year.
Outsourcing Pharma
SEPTEMBER 3, 2020
A company leader outlines the importance of increasing diversity in clinical trial patient populations, and how researchers can improve their results.
Pharma Marketing Network
SEPTEMBER 1, 2020
Despite the COVID-19 pandemic, digital display advertising will continue to grow this year with more investments in video ads. According to eMarketer, U.S. advertisers will increase investments in video by 11.3% this year to $35.45 billion, making it the only digital ad format to grow at a double-digit rate this year. For the first time ever, video will account for more than a quarter of all U.S. digital ad spending.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
SEPTEMBER 2, 2020
The decision allows use of the therapy in the EU in children as young as six years of age
pharmaphorum
SEPTEMBER 3, 2020
GlaxoSmithKline is opening a £10 million artificial intelligence (AI) research hub in King’s Cross, London, according to a press report. The area is being reimagined as a life sciences and technology hub and is already home to the Francis Crick Institute biomedical research organisation. King’s Cross is also home to Google’s DeepMind artificial intelligence company, which has already been involved in life sciences projects such as using the technology to predict acute kidney injury.
Outsourcing Pharma
SEPTEMBER 3, 2020
The companies will join forces to use IntelGenxâs polymeric film technologies for development of pharmaceutical-grade psychedelic drug treatments.
Med Ed 101
SEPTEMBER 2, 2020
Drug food interactions are common and there can be significant negative consequences from these interactions. A common misconception amongst healthcare professionals who may not have as much experience with drug interactions is that ALL statins interact with grapefruit juice. I have heard and read this type of comment before, and it is not true. Grapefruit […].
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
SEPTEMBER 4, 2020
The findings have validated confidence in the experimental vaccine, the firm noted
pharmaphorum
SEPTEMBER 2, 2020
Cancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to respond. But many patients still do not respond to therapies such as Merck & Co’s anti PD-1 therapy Keytruda (pembrolizumab), or go on to develop progressive disease, and pharma companies are looking for new second-line therapies.
Outsourcing Pharma
AUGUST 31, 2020
The company intends to enable pharma and biotech companies to have greater access to cryo-electronic microscopy for their research projects.
Med Ed 101
AUGUST 30, 2020
If you are a healthcare professional, inevitably, questions about the use of antidepressants in pregnancy come up in clinical practice. Why is paroxetine generally avoided in pregnancy? The primary reason that paroxetine is avoided in pregnancy is that it has demonstrated fetal risks. Through the previous FDA rating system, it was considered an FDA pregnancy […].
Pharma Times
SEPTEMBER 2, 2020
The oral therapy can be used as continued treatment for adults in first remission with acute myeloid leukaemia (AML)
pharmaphorum
SEPTEMBER 4, 2020
Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. The French pharma in April joined forces with the UK’s GSK to produce the vaccine, with Sanofi contributing an antigen that produces the immune reaction. Meanwhile GSK is producing the booster that reduces the amount of active ingredient necessary to produce an effect.
Outsourcing Pharma
SEPTEMBER 2, 2020
Learn about the latest appointments, acquisitions, awards and other news in life sciences, involving Florence, Nanoform and other notable companies.
pharmaphorum
SEPTEMBER 3, 2020
Sarah Rickwood looks at how COVID-19 is changing pharma’s commercial models and launch strategies. The terrible pandemic crisis we’ve had as our daily companion for six months is far from over, in part because it is in fact not one crisis, but three. There’s the initial pandemic crisis, which wreaked havoc on communities and stretched urgent care systems to the brink; the consequent healthcare system crisis, where the knock-on effects of the pandemic are still playing out in non-COVID patients a
pharmaphorum
SEPTEMBER 2, 2020
Gilead has joined forces with biotech Jounce Therapeutics to licence its immunotherapy JTX-1811 in a deal worth more than $800 million. The drug, JTX-1811, is a monoclonal antibody designed to selectively deplete immunosuppressive tumour-infiltrating T regulatory (TITR) cells. . The drug targets CCR8, a chemokine receptor enriched on TITR cells. When JTX-1811 binds to CCR8, it targets TITR cells for depletion by an enhanced antibody-dependent cellular cytotoxicity mechanism. .
pharmaphorum
SEPTEMBER 2, 2020
Bilal Babar from THE PLANNING SHOP tells us how the movement of birds and Swarm Technology have helped develop multiple market research tools. Flocks of birds wheeling, swooping and gliding in unison, as if choreographed, are a wonderful sight. The benefit to members of the flock are many including safety from predators, more eyes to spot food and natural selection – those that can’t keep up or fly in a very densely populated flock and make such sharp turns without colliding don’t survive.
pharmaphorum
SEPTEMBER 1, 2020
AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response. AZ already has late-stage trials ongoing in the UK, Brazil and South America, with trials planned to start in Japan and Russia, recruiting up to 50,000 patients globally.
pharmaphorum
SEPTEMBER 4, 2020
Leela Barham asks why companies may choose to not submit their drugs to NICE and keep them off routine commissioning – a trend that appears to be on the rise. Appraisal of a treatment by the National Institute for Health and Care Excellence (NICE) is voluntary; companies can simply choose not to submit, resulting in a statement from NICE that the appraisal was terminated due to non-submission.
pharmaphorum
SEPTEMBER 1, 2020
Novo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost-effectiveness watchdog NICE decided that there was no need to review it. After EU approval in April Novo said it had priced Rybelsus at parity with rival GLP-1 drugs in the UK, and NICE will not perform a single technology appraisal as a result, allowing the company to begin negotiations in England and Wales to get the drug included on NHS formularies.
pharmaphorum
SEPTEMBER 3, 2020
The Canadian government has reached agreements in principle with J&J and Novavax to buy their coronavirus vaccine candidates. Under the agreement with J&J, Canada would purchase up to 38 million doses of Janssen’s Ad26.COV2.S vaccine candidate on a not-for-profit basis for emergency pandemic use. Meanwhile, Novavax has agreed to supply up to 76 million doses of its candidate in the event of the vaccine gaining approval in the country.
pharmaphorum
SEPTEMBER 4, 2020
Personalized and precision medicines are exciting fields that focus on the development of treatment and prevention strategies for a single patient or patient group. The treatments are developed using cutting- edge technologies such as genomic sequencing and genetic engineering, helping to account for the individual variability in both patient and disease characteristics.
Expert insights. Personalized for you.
124 
Let's personalize your content